Humanized CAR-T Cells of Anti-BCAM and Anti-CD19 Against Relapsed and Refractory Multiple Myeloma

NCT04194931 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Relapsed or Refractory Multiple Myeloma

Interventions

BIOLOGICAL: Autologous BCMA CAR-T cells and CD19 CAR-T cells

Sponsor

The First Affiliated Hospital of Nanchang University